UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2323-2
Program Prior Authorization/Medical Necessity
Medication Zilbrysq® (zilucoplan)
P&T Approval Date 1/2024, 1/2025
Effective Date 4/1/2025
1. Background
Zilbrysq (zilucoplan) is a complement inhibitor indicated for the treatment of generalized
myasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody
positive.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Zilbrysq will be approved based on all of the following criteria1-3:
a. Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming all
of the following:
(1) Diagnosis of generalized myasthenia gravis (gMG)
-AND-
(2) Positive serologic test for anti-AChR antibodies
-AND-
(3) Patient has a Myasthenia Gravis Foundation of America (MGFA) Clinical
Classification of class II, III, or IV at initiation of therapy
-AND-
(4) Patient has a Myasthenia Gravis Activities of Daily Living scale (MG-ADL) total
score ≥ 6 at initiation of therapy
-AND-
b. One of the following:
(1) History of failure of at least two immunosuppressive agents over the course of at
least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate,
mycophenolate, etc.)
(2) Patient has a history of failure of at least one immunosuppressive therapy and has
required four or more courses of plasmapheresis/ plasma exchanges and/or
intravenous immune globulin over the course of at least 12 months without
symptom control
© 2025 UnitedHealthcare Services Inc.
1
-AND-
c. Patient is not receiving Zilbrysq in combination with another complement inhibitor
[e.g., Soliris (eculizumab), Ultomiris (ravulizumab-cwvz)] or a neonatal Fc receptor
blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab),
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]
-AND-
d. Prescribed by, or in consultation with, a neurologist
Authorization will be issued for 12 months.
B. Reauthorization
1. Zilbrysq will be approved based on all of the following criteria:
a. Submission of medical records (e.g., chart notes, laboratory tests) demonstrating all of
the following:
(1) Improvement and/or maintenance of at least a 2-point improvement (reduction in
score) in the MG-ADL score from pre-treatment baseline4
(2) Reduction in signs and symptoms of myasthenia gravis
(3) Maintenance, reduction, or discontinuation of dose(s) of baseline
immunosuppressive therapy (IST) prior to starting Zilbrysq
Note: Add on, dose escalation of IST, or additional rescue therapy from baseline to
treat myasthenia gravis or exacerbation of symptoms while on Zilbrysq therapy
will be considered as treatment failure
-AND-
b. Patient is not receiving Zilbrysq in combination with another complement inhibitor
[e.g., Soliris (eculizumab), Ultomiris (ravulizumab-cwvz)] or a neonatal Fc receptor
blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab),
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]
-AND-
c. Prescribed by, or in consultation with, a neurologist
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2025 UnitedHealthcare Services Inc.
2
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place
4. References:
1. Zilbrysq [package insert], Smyrna, GA: UCB, Inc.; April 2024.
2. Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with
generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3
study. Lancet Neurol. 2023;22(5):395-406. doi:10.1016/S1474-4422(23)00080-7
3. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for
Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122.
doi:10.1212/WNL.0000000000011124
4. Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. Measuring Clinical Treatment Response in
Myasthenia Gravis. Neurol Clin. 2018;36(2):339-353. doi:10.1016/j.ncl.2018.01.006
Program Prior Authorization/Medical Necessity - Zilbrysq® (zilucoplan)
Change Control
1/2024 New program.
1/2025 Annual review. Updated listing of examples of complement inhibitors
and neonatal Fc receptor blockers without change to clinical intent.
Updated references.
© 2025 UnitedHealthcare Services Inc.
3